Non-rodent animal models of osteosarcoma: A review

Helman, 2003, Mechanisms of sarcoma development, Nat Rev Cancer, 3, 685, 10.1038/nrc1168 Skubitz, 2007, Sarcoma, Mayo Clin Proc, 82, 1409, 10.4065/82.11.1409 Gorlick, 2009, Current concepts on the molecular biology of osteosarcoma, Cancer Treat. Res, 152, 467, 10.1007/978-1-4419-0284-9_27 Walia, 2017, Murine models of Osteosarcoma: a piece of the translational Puzzle, J Cell Biochem, 119, 4241, 10.1002/jcb.26601 Ottaviani, 2009, The Epidemiology of Osteosarcoma, Cancer Treat. Res, 152, 3, 10.1007/978-1-4419-0284-9_1 Ozaki, 2002, osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group, Cancer, 94, 1069, 10.1002/cncr.10258 Guijarro, 2014, Animal models in osteosarcoma, Front Oncol, 4, 1, 10.3389/fonc.2014.00189 Luetke, 2014, Osteosarcoma treatment – where do we stand? A state of the art review, Cancer Treat Rev, 40, 523, 10.1016/j.ctrv.2013.11.006 Mirabello, 2009, International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons, Int J Cancer, 125, 229, 10.1002/ijc.24320 McKenna, 1966, Osteogenic sarcoma in children, CA Cancer J. Clin., 16, 26, 10.3322/canjclin.16.1.26 Lindsey, 2017, Osteosarcoma overview, Rheumatol Therapy, 4, 25, 10.1007/s40744-016-0050-2 Roberts R.D., Wedekind M.F., Setty B.A. Chemotherapy regimens for patients with newly diagnosed malignant bone tumors. In: Cripe TP, Yeager ND, Eds.. Malignant Pediatric Bone Tumors - Treatment & Management. Pediatric Oncology. Cham: Springer; c 2015. p. 83–108. doi:10.1007/978-3-319-18099-1_6. Geller, 2010, Osteosarcoma: a review of diagnosis, management, and treatment strategies, Clin Adv. Hematol. Oncol., 8, 705 Fuchs, 1998, Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs, Ann. Oncol., 9, 893, 10.1023/A:1008391103132 He, 2014, Molecular mechanisms of chemo-resistance in Osteosarcoma (Review), Oncol Lett., 7, 1352, 10.3892/ol.2014.1935 Kunz, 2019, Optimization of the chicken chorioallantoic membrane assay as reliable in vivo model for the analysis of osteosarcoma, PLoS ONE, 14, 1, 10.1371/journal.pone.0215312 Steeg, 2016, Targeting metastasis, Nat Rev Cancer, 16, 201, 10.1038/nrc.2016.25 Khanna, 2014, Toward a drug development path that targets metastatic progression in osteosarcoma, Clin Cancer Res, 20, 4200, 10.1158/1078-0432.CCR-13-2574 Anderson, 2019, A framework for the development of effective anti-metastatic agents, Nat Rev Clin Oncol, 16, 185, 10.1038/s41571-018-0134-8 Fan, 2020, Understanding and modeling metastasis biology to improve therapeutic strategies for combating osteosarcoma progression, Front Oncol, 10, 1, 10.3389/fonc.2020.00013 An, 2006, Animal models of osteomyelitis, Int. J. Artif. Organs, 29, 407, 10.1177/039139880602900411 Saalfrank, 2016, A porcine model of osteosarcoma, Oncogenesis, 5, e210, 10.1038/oncsis.2016.19 Kendall, 2005, A network of genetic events sufficient to convert normal human cells to a tumorigenic state, Cancer Res, 65, 9824, 10.1158/0008-5472.CAN-05-1543 Manjunathan, 2015, Chicken chorioallantoic membrane as a reliable model to evaluate osteosarcoma-an experimental approach using SaOS2 cell line, Biol. Proc. Online, 17, 1, 10.1186/s12575-015-0022-x Haeckel, 1998, Antisense inhibition of urokinase: effect on malignancy in a human osteosarcoma cell line, Int J Cancer, 77, 153, 10.1002/(SICI)1097-0215(19980703)77:1<153::AID-IJC23>3.0.CO;2-E Liu, 2013, The histone methyltransferase EZH2 mediates tumor progression on the chick chorioallantoic membrane assay, a novel model of head and neck squamous cell carcinoma, Transl. Oncol., 6, 273, 10.1593/tlo.13175 Ribatti, 2017, The chick embryo chorioallantoic membrane (CAM) assay, Reprod Toxicol, 70, 97, 10.1016/j.reprotox.2016.11.004 Balke, 2010, Morphologic characterization of osteosarcoma growth on the chick chorioallantoic membrane, BMC Res. Notes, 3, 1, 10.1186/1756-0500-3-58 Tome, 2016, The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing ανβ3 integrin in chick embryo and nude mouse models, Oncotarget, 7, 87031, 10.18632/oncotarget.13497 Guder, 2020, analysis of drug sensitivity of human high-grade osteosarcoma in a chick chorioallantoic membrane (CAM) model: a proof of principle study, BMC Res. Notes, 13, 1, 10.1186/s13104-020-05269-x Kalla, 2020, Genetically engineered pigs to study cancer, Int. J. Mol. Sci, 21, 1, 10.3390/ijms21020488 Perleberg, 2018, Genetically engineered pigs as models for human disease, Dis. Models Mech, 11, 10.1242/dmm.030783 Flisikowska, 2014, Genetically modified pigs to model human diseases, J. Appl. Genet., 55, 53, 10.1007/s13353-013-0182-9 Hoffe, 2019, The use of pigs as a translational model for studying neurodegenerative diseases, Front. Physiol., 10, 1, 10.3389/fphys.2019.00838 Levine, 2009, The first 30 years of p53: growing ever more complex, Nature Rev, 9, 749 Overholtzer, 2003, The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability, Proc. Natl. Acad. Sci. USA, 100, 11547, 10.1073/pnas.1934852100 Miller, 1990, Frequency and structure of p53 rearrangements in human osteosarcoma, Cancer Res, 15, 7950 Miller, 1996, Alterations of the p53, Rb and MDM2 genes in osteosarcoma, J. Cancer Res. Clin. Oncol, 122, 559, 10.1007/BF01213553 Toguchida, 1992, Mutation spectrum of the p53 gene in bone and soft tissue sarcomas, Cancer Res, 15, 6194 Leuchs, 2012, Inactivation and inducible oncogenic mutation of p53 in gene targeted pigs, PLoS ONE, 7, e43323, 10.1371/journal.pone.0043323 Sieren, 2014, Development and translational imaging of a TP53 porcine tumorigenesis model, J Clin Invest, 124, 4052, 10.1172/JCI75447 Tanihara, 2018, Generation of a TP53-modified porcine cancer model by CRISPR/Cas9-mediated gene modification in porcine zygotes via electroporation, PLoS ONE, 13, 10.1371/journal.pone.0206360 Flisikowska, 2016, Pigs as models of human cancers, Theriogenology, 86, 433, 10.1016/j.theriogenology.2016.04.058 Roth, 2013, Assessment of juvenile pigs to serve as human pediatric surrogates for pre-clinical formulation pharmacokinetic testing, AAPS J, 15, 763, 10.1208/s12248-013-9482-6 Myers, 2001, Identification of multiple constitutive and inducible hepatic cytochrome P450 enzymes in market weight swine, Drug Metab. Dispos., 29, 908 Withrow, 2010, Cross talk from pets to people: translational osteosarcoma treatments, ILAR J, 51, 208, 10.1093/ilar.51.3.208 Castillo-Tandazo, 2019, Osteosarcoma in the post genome era: preclinical models and approaches to identify tractable therapeutic targets, Curr. Osteoporos Rep, 17, 343, 10.1007/s11914-019-00534-w Kirpensteijn, 2008, TP53 gene mutations in canine osteosarcoma, Vet. Surg, 37, 454, 10.1111/j.1532-950X.2008.00407.x Sakthikumar, 2018, SETD2 is recurrently mutated in whole-exome sequenced canine osteosarcoma, Cancer Res, 78, 3421, 10.1158/0008-5472.CAN-17-3558 Behjati, 2017, Recurrent mutation of IGF signaling genes and distinct patterns of genomic rearrangement in osteosarcoma, Nat. Commun, 8, 1, 10.1038/ncomms15936 Zapata, 2019, Risk-modeling of dog osteosarcoma genome scans shows individuals with Mendelian-level polygenic risk are common, BMC Genomics, 20, 1, 10.1186/s12864-019-5531-6 Karuppaiah, 2016, FGF signaling in the osteoprogenitor lineage non-autonomously regulates postnatal chondrocyte proliferation and skeletal growth, Development, 143, 1811, 10.1242/dev.131722 Perry, 2014, Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma, Proc. Natl. Acad Sci. U. S. A., 111, E5564, 10.1073/pnas.1419260111 Fernanda Amary, 2014, Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neoadjuvant chemotherapy, Cancer Med, 3, 980, 10.1002/cam4.268 Al-Khan, 2017, Immunohistochemical validation of spontaneously arising canine osteosarcoma as a model for human osteosarcoma, J Comp Pathol, 157, 256, 10.1016/j.jcpa.2017.07.005 Roy, 2017, Comparative proteomic investigation of metastatic and non-metastatic osteosarcoma cells of human and canine origin, PLoS ONE, 12, 1, 10.1371/journal.pone.0183930 London, 2014, Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study, PLoS ONE, 9, e87585, 10.1371/journal.pone.0087585 Nguyen, 2012, The CRM1 nuclear export protein in normal development and disease, Int. J. Biochem. Mol. Biol, 3, 137 Turner, 2012, Nuclear export of proteins and drug resistance in cancer, Biochem. Pharmacol, 83, 1021, 10.1016/j.bcp.2011.12.016 Turner, 2008, CRM1-mediated nuclear export of proteins and drug resistance in cancer, Curr. Med. Chem, 15, 2648, 10.2174/092986708786242859 Yang, 2017, Synergistic effects of Bortezomib and JQ1 for human and canine osteosarcoma treatments [abstract, 77 Kirpensteijn, 2002, Lobaplatin as an adjuvant chemotherapy to surgery in canine appendicular osteosarcoma: a phase II evaluation, Anticancer Res, 22, 2765 Kirpensteijn, 2002, Growth hormone gene expression in canine normal growth plates and spontaneous osteosarcoma, Mol. Cell Endocrinol, 197, 179, 10.1016/S0303-7207(02)00269-1 Kirpensteijn, 2002, Prognostic significance of a new histologic grading system for canine osteosarcoma, Vet Pathol, 39, 240, 10.1354/vp.39-2-240 Lascelles, 2005, Improved survival associated with post-operative wound infection in dogs treated with limb-salvage surgery for osteosarcoma, Ann Surg Oncol, 12, 1073, 10.1245/ASO.2005.01.011 Naik, 2018, Comparative oncology evaluation of intravenous recombinant oncolytic vesicular stomatitis virus therapy in spontaneous canine cancer, Mol. Cancer Ther, 17, 316, 10.1158/1535-7163.MCT-17-0432 Modiano, 2012, Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer, Mol Ther, 12, 2234, 10.1038/mt.2012.149 MacEwen, 1989, Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide, J. Natl. Cancer Inst, 81, 935, 10.1093/jnci/81.12.935 Kurzman, 1995, Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin, Clin Cancer Res, 1, 1596 Meyers, 2008, Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—A report from the children’s oncology group, J Clin Oncol, 26, 633, 10.1200/JCO.2008.14.0095 Fritz, 2016, A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma, Vet Med Sci, 2, 179, 10.1002/vms3.32 Mason, 2016, Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma, Clin Cancer Res, 22, 4380, 10.1158/1078-0432.CCR-16-0088